MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. (2021)

First Author: Verstovsek S
Attributed to:  Unravelling biological heterogeneity in neoplastic myeloproliferative stem cells funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.2217/fon-2020-1048

PubMed Identifier: 33423550

Publication URI: http://europepmc.org/abstract/MED/33423550

Type: Journal Article/Review

Volume: 17

Parent Publication: Future oncology (London, England)

Issue: 12

ISSN: 1479-6694